GBP slightly weaker, underperforms G10 currencies – Scotiabank
The Pound Sterling (GBP) is soft, down a modest 0.2% but underperforming most of the G10 currencies as we head into Friday’s NA session, Scotiabank's Chief FX Strategists Shaun Osborne and Eric Theoret report.
BoE signals dovish stance amid uncertainty on neutral rates
"This week’s price action has been mixed, and broadly driven by external developments in the absence of high-level domestic data. Domestic risk returns next week as we look to industrial production and trade, as well as scheduled appearances from BoE MPC members Taylor and Ramsden. Comments from the BoE have been limited in the new year, though messaging has largely leaned dovish with uncertainty about the central bank’s proximity to ‘neutral’ rates."
"Finally, we see some added near-term risk from the turn in sentiment as we note the signs of exhaustion in risk reversals stalling out after fading a considerable portion of the premium for protection against GBP weakness over the past month or so."
"This week’s price action has been mixed with a clear bearish reversal from a short-lived multi-month high in the mid-1.35s. Momentum indicators remain close to neutral as the RSI hovers around 50. We remain neutral absent a clear break below the 200 day MA (1.3393), after which we see risk of an extension to the 50 day MA at 1.3304. We look to a near-term range bound between 1.3380 and 1.3480."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Stan Druckenmiller backs trade.xyz, ICE partnership targets US perpetual futures
Record High Monthly Active Users Can't Hide Risks: Pinterest (PINS.US) Q3 Revenue and Profit Both Miss Expectations, Q4 Guidance Weak, Shares Drop Over 10% After Hours
Pinterest (PINS.US), the image-based social networking and shopping platform, released its Q3 2026 financial report on Thursday, October 29 local time. Although global monthly active users (MAU) reached a historic high of 661 million and net sales achieved double-digit growth, both the company's revenue and adjusted profit for the quarter fell short of Wall Street expectations.
Core business achieves fastest growth in over a decade! Gilead (GILD.US) Q3 is a mix of good and bad news: Raises full-year sales guidance but Biktarvy will face a 38% price cut pressure from U.S. Medicare
On October 29th (Thursday) local time, US biopharmaceutical giant Gilead Sciences (GILD.US) released its financial report for the third quarter of 2026. Driven by double-digit growth in its flagship HIV drug portfolio, the company's product sales in the quarter increased by 13% year-over-year to $8.3 billion, surpassing market expectations.
